Ascentage Pharma Group International ((HK:6855)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: Ascentage Pharma Group is conducting a pivotal study titled A Global, Multicenter, Randomized, Double-blind, Phase 3 Pivotal Registrational Clinical Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (GLORA-3). The study aims to evaluate the efficacy of the combination of APG-2575 (Lisaftoclax) and azacitidine compared to a placebo with azacitidine in patients with acute myeloid leukemia (AML) who are not eligible for standard induction chemotherapy.
Intervention/Treatment: The study tests the combination of APG-2575 (Lisaftoclax), an oral drug administered daily, with azacitidine injections, against a placebo combined with azacitidine. This treatment targets AML in patients who cannot undergo standard chemotherapy.
Study Design: This interventional study is randomized and follows a parallel assignment model. It is double-blind, meaning both participants and investigators are unaware of the group assignments, with the primary purpose of treatment.
Study Timeline: The study began on April 24, 2024, with the last update submitted on August 18, 2025. These dates are crucial as they indicate the study’s progress and ongoing recruitment status.
Market Implications: The update on this study could positively influence Ascentage Pharma’s stock performance by enhancing investor confidence in their innovative treatment approach for AML. The success of this study could position the company favorably against competitors in the oncology market.
The study is ongoing, and further details are available on the ClinicalTrials portal.